GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ABCL · Jun 30, 2026

AbCellera Biologics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001703057-26-000046General Corporate

Capex intensity25thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

52.64% · OPTIONAL · VALID

Operating cash generation100thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

640.07% · OPTIONAL · VALID

Revenue growth24thOwn-history percentile · N=17

Evidence method

Yoy · gp.fundamentals.revenue

-76.29% · CORE · VALID

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

187.11% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating margin0thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.operating_margin

-1550.05% · CORE · VALID

R&D intensity100thOwn-history percentile · N=20

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1135.48% · OPTIONAL · VALID

SBC intensity95thOwn-history percentile · N=20

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

303.36% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History18 statesSelf-history eligible

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 46.07%
Current: 52.64%
Delta: 6.57%

Cash Generation Increased

Previous: -403.16%
Current: 640.07%
Delta: 1043.24%

Growth Decreased

Previous: 96.34%
Current: -76.29%
Delta: -172.63%

Inventory Pressure Increased

Previous: 94.53%
Current: 187.11%
Delta: 92.58%

Profitability Decreased

Previous: -691.75%
Current: -1550.05%
Delta: -858.30%

R And D Intensity Increased

Previous: 561.18%
Current: 1135.48%
Delta: 574.30%

Sbc Intensity Increased

Previous: 144.47%
Current: 303.36%
Delta: 158.88%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2025

Similarity: 66%
Compared: 6 dimensions
Coverage: 100%

Growth 9.8 · Profitability 0.0 · Sbc Intensity 5.0 · Capex Intensity 43.8 · Cash Generation 68.8 · R And D Intensity 0.0

Jun 30, 2023

Similarity: 64%
Compared: 5 dimensions
Coverage: 83%

Profitability 11.1 · Sbc Intensity 5.0 · Capex Intensity 75.0 · Cash Generation 22.2 · R And D Intensity 11.1

Dec 31, 2023

Similarity: 55%
Compared: 5 dimensions
Coverage: 83%

Profitability 9.1 · Sbc Intensity 4.1 · Capex Intensity 56.8 · Cash Generation 81.8 · R And D Intensity 9.1

Mar 31, 2026

Similarity: 54%
Compared: 6 dimensions
Coverage: 100%

Growth 57.7 · Profitability 30.0 · Sbc Intensity 40.0 · Capex Intensity 0.0 · Cash Generation 80.0 · R And D Intensity 25.0

Jun 30, 2024

Similarity: 52%
Compared: 6 dimensions
Coverage: 100%

Growth 20.9 · Profitability 0.0 · Sbc Intensity 5.0 · Capex Intensity 67.3 · Cash Generation 92.3 · R And D Intensity 7.7

Research Graph

Related governed research

Analogous To · ABCL state analogue 1 →Compared To · Pharmaceutical Preparations peers →Analogous To · ABCL state analogue 4 →Analogous To · ABCL state analogue 5 →Analogous To · ABCL state analogue 3 →Analogous To · ABCL state analogue 2 →Has State · AbCellera Biologics Inc. →Transitioned To · ABCL Fundamental State →Transitioned To · ABCL CAPEX_INTENSITY_INCREASED →Transitioned To · ABCL CASH_GENERATION_INCREASED →Transitioned To · ABCL GROWTH_DECREASED →Transitioned To · ABCL INVENTORY_PRESSURE_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.